|
Interferon alfa-2b
resources
|
|
|
|
|
|
DRUG INFO
Interferon alfa-2b
Drug Name:
Interferon alfa-2b
Indication: For treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma
Pharmacology: Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.
Mechanism Of Action: Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which upon dimerization activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.
Drug Category: Antiviral Agents; Immunomodulatory Agents; Antineoplastic Agents; interferons (08:18.20);antineoplastic agents (10:00.00)
Brand Names/Synonyms: Interferon alpha-2 precursor;Interferon alpha-A;LeIF A; Intron A (Schering Corp)
Dosage Forms: LIQUID
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Not Available
Chemical Formula: C860H1353N229O255S9
Half Life: Not Available
Drug Type: Approved Drug
# Accession No: BIOD00066
CAS Registry Number: 98530-12-2
|
|
|
|
|
|
Interferon alfa-2b News
(When available)
Schering-Plough Initiates PEG-INTRON(R) Maintenance Study in ... Jan 12, 2006
PR Newswire (press release), Psychiatric adverse events, which include insomnia, were common (57%) with PEG-INTRON, but similar to INTRON A (58%). Depression was most common at 29%. ...
Older HCV Patients Have Tough Time with Combination Therapy Jan 9, 2006
MedPage Today, ...patients with chronic hepatitis C (HCV) infections are less likely than younger patients to tolerate combination therapy with Intron A (recombinant IFN alfa-2b ...
Schering-Plough Initiates PEG-INTRON(R) Maintenance Study in ... Jan 12, 2006
Yahoo! News (press release) There are no new adverse events specific to PEG-INTRON as compared to INTRON® A (interferon alfa-2b, recombinant) for Injection, however, the incidence of ...
Schering-Plough Announces PEG-Intron and Rebetol Approved in Japan ... Dec 22, 2005
DG News There are no new adverse events specific to PEG-Intron as compared to Intron® A (interferon alfa-2b, recombinant) for Injection, however, the incidence of ...
Keryx Biopharmaceuticals, Inc. Announces Appointment of Senior ... Jan 4, 2006
PR Newswire (press release), Dr. Spicehandler played a major leadership role in the development and approval of several well-known drugs, including: (1) intron-A(R) (recombinant interferon ...
Interferon with Ribavirin is safe and effective for children with ... Jan 1, 2006
Xagena.it, Nearly half of 118 children with chronic Hepatitis C virus ( HCV ) treated with a combination of Interferon-alpha-2b ( Intron A ) and an optimized dose of ...
|
|
|
